Christophe Bernard.

Christophe Bernard

Director of research
Institute of Systems Neuroscience

Christophe Bernard is director of research at the Institute of Systems Neuroscience, INSERM U1106. His main interest is to understand brain dynamics in health and disease, with a focus on epilepsy.

He acts as a reviewing editor for Science Advances, and formerly for Science and the Journal of Neuroscience. He created and is the editor-in-chief of eNeuro, the online open-access journal of the Society for Neuroscience. eNeuro is designed to serve and educate the neuroscience community, promoting reproducibility, publishing negative results and sensitizing scientists to open science and better data interpretation with a focus on statistics and experimental bias.

Bernard obtained his Ph.D. in neuroscience from Pierre and Marie Curie University, did his postdoctoral research at the University of Southampton and spent a sabbatical at Baylor College of Medicine. He participated in the development of organic technologies to record and control brain activity, which earned him the Felix Innovation Prize, and in the development of the Virtual Mouse Brain.

Explore more from The Transmitter

Headshots of Yale researchers Yong-Hui Jiang and Jiangbing Zhou.

Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions

Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.

By Natalia Mesa
3 June 2026 | 11 min read

What counts as a ‘naturalistic’ behavior?

Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.

By Paul Middlebrooks
3 June 2026 | 1 min read
Research image of brain cells involved with Amyotrophic lateral sclerosis (ALS) illuminated through genetic tools

Allen Institute sets sights on treatments for five brain diseases

The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.

By Calli McMurray
2 June 2026 | 5 min read